盐酸羟考酮注射液用于下腹部手术全麻苏醒期急性疼痛的临床观察

发布时间：2018-05-20 06:12

本文选题：盐酸羟考酮注射液 + 地佐辛　；参考：《中国新药杂志》2017年06期

【摘要】：目的:观察盐酸羟考酮注射液在下腹部手术全麻苏醒期急性疼痛的疗效及不良反应情况。方法:选择下腹部手术患者120例,随机分为3组:羟考酮组(Q组)、地佐辛组(D组)和吗啡组(M组),每组40例,分别于手术结束前30 min静脉注射羟考酮0.1 mg·kg-1、地佐辛0.1 mg·kg-1和吗啡0.1 mg·kg-1。观察并记录3组患者停药后苏醒时间、拔管时间、术后疼痛视觉模拟评分(visual analogue scale,VAS)、警觉/镇静评分(OAA/S)、苏醒期躁动(emergence agitation,EA)、拔管后10 min的血气分析和药物不良反应(呼吸抑制、恶心、呕吐等)。结果:3组患者一般资料无统计学差异。3组患者的术后苏醒时间、拔管时间、EA、拔管后10 min的血气分析、呼吸抑制、恶心、呕吐无统计学意义。Q组术后VAS评分优于其他2组,D组OAA/S评分低于M组(P0.05)。结论:手术结束前30 min给予羟考酮注射液0.1 mg·kg-1可有效预防下腹部全麻术后苏醒期急性疼痛的发生,且效果优于地佐辛和吗啡。
[Abstract]:Objective: to observe the curative effect and adverse reaction of hydroxycodone hydrochloride injection in acute pain during general anesthesia of lower abdominal operation. Methods: one hundred and twenty patients undergoing lower abdominal surgery were randomly divided into three groups: hydroxycodone group (Q group) and dizoxine group (D group) and morphine group (40 cases), each group (40 cases) received intravenously administration of hydroxycodone 0.1 mg kg-1, dizoxin 0.1 mg kg-1 and morphine 0.1 mg kg-1 30 min before the end of operation. The recovery time, extubation time, visual analogue scale score, alertness / sedation score of OAA / sedation were observed and recorded in the three groups. Blood gas analysis and adverse drug reactions (respiratory inhibition, nausea) 10 min after extubation were observed and recorded. Vomit, etc. Results there was no significant difference in general data among the 3 groups. 3. The postoperative recovery time, extubation time, blood gas analysis, respiratory inhibition, nausea, 10 min after extubation. The postoperative VAS score in group Q was higher than that in group D (P 0.05), and the score of OAA/S in group D was lower than that in group M (P 0.05). Conclusion: administration of 0.1 mg kg-1 at 30 min before the end of operation can effectively prevent acute pain after lower abdominal general anesthesia, and the effect is better than that of dizosin and morphine.
【作者单位】：北京大学肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室;
【分类号】：R614.2

【相似文献】